Claims for Patent: 11,419,769

Summary for Patent: 11,419,769

Title:	Sublingual films
Abstract:	The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
Inventor(s):	Bryson; Nathan John (Toronto, CA), Giovinazzo; Anthony John (Caledon, CA), Barnhart; Scott David (York, PA), Koons; Michael Clinton (York, PA)
Assignee:	Sunovion Pharmaceuticals Inc. (Marlborough, MA)
Application Number:	16/409,257
Patent Claims:	1. A pharmaceutical composition in unit dosage form formulated for sublingual administration, wherein said unit dosage form is a film comprising: (i) 30 to 75% (w/w) of an acid addition salt of apomorphine, (ii) 0.5 to 10% (w/w) of a low molecular weight polymer having a weight average molecular weight of 5 kDa to 50 kDa selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose; and (iii) 4 to 20.+-.6% (w/w) of a high molecular weight polymer having a weight average molecular weight of greater than 60 kDa selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, and methyl cellulose; and wherein said film is a bilayer film comprising a first layer comprising said acid addition salt of apomorphine and a second layer comprising a pH neutralizing agent that is pyridoxine. 2. The pharmaceutical composition of claim 1, further comprising from 0.2 to 5% (w/w) of permeation enhancer. 3. The pharmaceutical composition of claim 1, further comprising from 0.2 to 5% (w/w) of glycerol monostearate. 4. The pharmaceutical composition of claim 1, further comprising from 3 to 12% (w/w) of plasticizing agent. 5. The pharmaceutical composition of claim 4, wherein said plasticizing agent is a polyol, oleic acid, or triacetin. 6. The pharmaceutical composition of claim 5, wherein said plasticizing agent is a polyol selected from the group consisting of sorbitol, mannitol, maltitol, xylitol, glycerol, propylene glycol, and polyethylene glycol. 7. The pharmaceutical composition of claim 1, further comprising from 1 to 50% (w/w) of a hydrolyzed starch. 8. The pharmaceutical composition of claim 7, wherein said hydrolyzed starch is a dextrin. 9. The pharmaceutical composition of claim 7, wherein said hydrolyzed starch is a maltodextrin. 10. The pharmaceutical composition of claim 1, further comprising an antioxidant. 11. The pharmaceutical composition of claim 1, further comprising said pharmaceutical composition further comprises from 0.05 to 2.5% (w/w) of a metabisulfite. 12. The pharmaceutical composition of claim 1, wherein said unit dosage form is stable for a period of at least 2 months at 40.degree. C., when packaged in a sealed plastic-lined aluminum foil. 13. The pharmaceutical composition of claim 1, wherein said film comprises particles of said acid addition salt of apomorphine. 14. The pharmaceutical composition of claim 13, wherein said acid addition salt of apomorphine is apomorphine hydrochloride. 15. The pharmaceutical composition of claim 13, wherein said particles have an effective particle size of from 20 nm to 10 .mu.m. 16. The pharmaceutical composition of claim 1, wherein said unit dosage form when placed in 1 mL of unbuffered water at pH 7 results in a solution having a pH of between 4.5 and 8.5. 17. The pharmaceutical composition of claim 1, wherein said film comprises 12.+-.3 mg of apomorphine hydrochloride. 18. The pharmaceutical composition of claim 1, wherein said film comprises 22.+-.4 mg of apomorphine hydrochloride. 19. The pharmaceutical composition of claim 1, wherein said film comprises 30.+-.5 mg of apomorphine hydrochloride. 20. A method of treating Parkinson's disease in a subject, said method comprising sublingual administration of a pharmaceutical composition of claim 1 in an amount effective to treat said subject. 21. The method of claim 20, wherein said treating comprises alleviating an OFF episode associated with Parkinson's disease in said subject.